L., Garca-Domnguez J., Arias J
In reality, those disclosures are often nonexistent, buried in hashtags or difficult to see
Since then, many sellers have pivoted to personalized formulations that add ingredients such as vitamin B-12 and argue the result is not essentially a copy. But FDA said on April 1, 2026 that a compounded product combining semaglutide and another active ingredient such as vitamin B12 may still be essentially a copy unless a prescriber documents a patient-specific significant difference. In March 2026, Eli Lilly has warned against the practice of compounding tirzepatide with vitamin B-12
2D-gel based proteomics unravels neurogenesis and energetic metabolism dysfunction of the olfactory bulb in CUMS rat model
Theres been some confusion and a bit of misinformation about who we are and where we stand, especially around the topic of GLP-1s
- - - - - - - - About the Author: Dr